Verschoyle Richard D, Brown Karen, Steward William P, Gescher Andreas J
Cancer Biomarkers and Prevention Group, Department of Cancer Studies, RKCSB, LRI, University of Leicester, Leicester, LE2 7LX, UK.
Cancer Chemother Pharmacol. 2008 Jul;62(2):369-72. doi: 10.1007/s00280-007-0611-8. Epub 2007 Oct 2.
Silibinin is a flavonolignan extracted from milk thistle with cancer chemopreventive activity in preclinical models of prostate and colorectal cancer. A milk thistle extract, of which silibin is a major component, has recently been shown to exacerbate mammary carcinogenesis in two rodent models. We tested the hypothesis that consumption of silibinin or silipide, a silibinin formulation with pharmaceutical properties superior to the unformulated agent, affect breast cancer development in the C3(1) SV40 T,t antigen transgenic multiple mammary adenocarcinoma mouse model. Mice received silibinin or silipide (0.2% silibinin equivalents) with their diet from weaning, and tumour development was monitored by weekly palpation and the number and weight of neoplasms at the end of the experiment. Intervention neither promoted, nor interfered with, tumour development. The result suggests that promotion of carcinogenesis is not a feature of silibinin consistent across rodent models of mammary carcinogenesis.
水飞蓟宾是一种从水飞蓟中提取的黄酮木脂素，在前列腺癌和结直肠癌的临床前模型中具有癌症化学预防活性。一种以水飞蓟宾为主要成分的水飞蓟提取物，最近已被证明在两种啮齿动物模型中会加剧乳腺癌的发生。我们测试了以下假设：食用水飞蓟宾或水飞蓟素（一种具有优于未配方制剂的药学特性的水飞蓟宾制剂）会影响C3(1) SV40 T,t抗原转基因多发性乳腺腺癌小鼠模型中的乳腺癌发展。小鼠从断奶开始在饮食中摄入水飞蓟宾或水飞蓟素（相当于0.2%的水飞蓟宾），通过每周触诊监测肿瘤发展，并在实验结束时监测肿瘤的数量和重量。干预既没有促进也没有干扰肿瘤发展。结果表明，致癌作用的促进并非水飞蓟宾在所有乳腺致癌啮齿动物模型中都具有的特征。
